Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
A bispecific encore, plus two in vivo Cars
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
The first test of Recursion's Exscientia move
The combined company's MALT1 inhibitor has started phase 1.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Relay pulls ahead of Lilly
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
